These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 19157429)
21. Prostate screening frequency questioned. Health News; 2002 Jul; 8(7):9. PubMed ID: 12132511 [No Abstract] [Full Text] [Related]
22. Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer. Loeb S; Carter HB Urol Oncol; 2009; 27(6):583-4. PubMed ID: 19879470 [No Abstract] [Full Text] [Related]
23. Re: Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor: B. I. Rini, L. Fong, v. Weinberg, B. Kavanaugh and E. J. Small. J Urol 2006; 175: 2087-2091. Brú A J Urol; 2007 Apr; 177(4):1585; author reply 1585-6. PubMed ID: 17382784 [No Abstract] [Full Text] [Related]
24. Hemodilution of prostate-specific antigen levels among obese men. Rundle A; Richards C; Neugut AI Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2343; author reply 2343-4. PubMed ID: 19661096 [No Abstract] [Full Text] [Related]
25. A framework for the identification of men at increased risk for prostate cancer. Roobol MJ; Schröder FH; Crawford ED; Freedland SJ; Sartor AO; Fleshner N; Andriole GL J Urol; 2009 Nov; 182(5):2112-20. PubMed ID: 19758625 [TBL] [Abstract][Full Text] [Related]
26. Re: E. David Crawford, Per-Anders Abrahamsson. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol 2008;54:262-73. Kvåle R; Hernes E; Bray F Eur Urol; 2009 May; 55(5):e88-9; author reply e90-1. PubMed ID: 19062155 [No Abstract] [Full Text] [Related]
27. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer. D'Amico AV; Chen MH J Clin Oncol; 2009 Aug; 27(22):3575-6. PubMed ID: 19506151 [No Abstract] [Full Text] [Related]
28. The association of body mass index and prostate-specific antigen in a population-based study. Walsh PC J Urol; 2005 Nov; 174(5):1825. PubMed ID: 16217299 [No Abstract] [Full Text] [Related]
30. Re: B.J. De Castro and K. C. Baker: Effect of flexible cystoscopy on serum prostate-specific antigen values (Urology 2009; 73:237-240). Romics I Urology; 2009 Jul; 74(1):234. PubMed ID: 19567303 [No Abstract] [Full Text] [Related]
31. Brachytherapy doses for prostate cancer customized to risk factors: is it more important "how much" or "where"? In regard to Stone et al. (Int J Radiat Oncol Biol Phys 2007;69:1472-1477). Oton CA; Oton F Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):962; author reply 962-3. PubMed ID: 18514795 [No Abstract] [Full Text] [Related]
32. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men. Ghafoori M; Varedi P; Hosseini SJ; Asgari M; Shakiba M Urol J; 2009; 6(3):182-8. PubMed ID: 19711272 [TBL] [Abstract][Full Text] [Related]
33. Re: Serum prostate specific antigen as prescreening test for prostate cancer. Catalona WJ J Urol; 1993 May; 149(5):1149-50. PubMed ID: 7683342 [No Abstract] [Full Text] [Related]
39. Precursor isoform of prostate-specific antigen and human kallikrein 2: two new promising biomarkers for the unsolved challenge of early prostate cancer detection. Ficarra V; Novara G; Galfano A Eur Urol; 2009 Mar; 55(3):556-9. PubMed ID: 19111385 [No Abstract] [Full Text] [Related]